I den anden pivotale undersøgelse (forsøg 2) var det primære endepunkt SPID30, som ligeledes var statistisk signifikant sammenlignet med placebo (p < 0, 0001).
In the second pivotal study (study 2), the primary endpoint was SPID30, which was also statistically significant compared to placebo (p < 0.0001).